



# Changes in Testosterone Levels Following Surgical Sperm Retrieval in Men with Non-Obstructive Azoospermia: Systematic Review and Meta-Analysis

Wael Zohdy<sup>1,2</sup>, Rupin Shah<sup>2,3</sup>, Christopher Chee Kong Ho<sup>2,4</sup>, Gokhan Calik<sup>2,5</sup>, Vineet Malhotra<sup>2,6</sup>,  
Bircan Kolbaşı Erkan<sup>2,7</sup>, Mesut Berkan Duran<sup>2,8</sup>, Georgios Tsampoukas<sup>2,9,10</sup>, Garaz Radion<sup>2,11</sup>,  
Ramadan Saleh<sup>2,12,13</sup>, Ahmed M. Harraz<sup>2,14,15,16</sup>, Parviz Kavoussi<sup>2,17</sup>, Eric Chung<sup>2,18</sup>, Edmund Ko<sup>2,19</sup>,  
Luca Boeri<sup>2,20</sup>, Naveen Kumar<sup>2,21</sup>, Selahittin Çayan<sup>2,22</sup>, Amarnath Rambhatla<sup>2,23</sup>, Osvaldo Rajmil<sup>2,24,25</sup>,  
Mohamed Arafat<sup>1,2,26,27</sup>, Rossella Cannarella<sup>2,28,29</sup>, Omer Raheem<sup>2,30</sup>, Taymour Mostafa<sup>1,2</sup>,  
Widi Atmoko<sup>2,31</sup>, Taha Abo-Elmagd Abdel-Meguid Hamoda<sup>2,32,33</sup>, Armand Zini<sup>2,34</sup>, Ashok Agarwal<sup>2,35</sup>

<sup>1</sup>Department of Andrology, Sexology & STIs, Faculty of Medicine, Cairo University, Cairo, Egypt, <sup>2</sup>Global Andrology Forum, Moreland Hills, OH, USA, <sup>3</sup>Department of Urology, Lilavati Hospital and Research Centre, Mumbai, India, <sup>4</sup>Department of Surgery, School of Medicine, Taylor's University, Subang Jaya, Selangor, Malaysia, <sup>5</sup>Department of Urology, Istanbul Medipol University, Istanbul, Türkiye, <sup>6</sup>Department of Urology, VNA Hospital, New Delhi, India, <sup>7</sup>Department of Histology and Embryology, Istanbul Medipol University, Istanbul, <sup>8</sup>Department of Urology, Pamukkale University School of Medicine, Denizli, Türkiye, <sup>9</sup>Department of Urology, Princess Alexandra Hospital, Harlow, <sup>10</sup>U-merge Ltd, Urology for Emerging Countries, London, UK, <sup>11</sup>Department of Urology, University Hospital of Tübingen, Tübingen, Germany, <sup>12</sup>Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Sohag University, Sohag, <sup>13</sup>Ajyal IVF Center, Ajyal Hospital, Sohag, <sup>14</sup>Mansoura University Urology and Nephrology Center, Mansoura, Egypt, <sup>15</sup>Department of Surgery, Urology Unit, Farwaniya Hospital, Farwaniya, <sup>16</sup>Department of Urology, Sabah Al Ahmad Urology Center, Kuwait City, Kuwait, <sup>17</sup>Austin Fertility & Reproductive Medicine/Westlake IVF, Austin, TX, USA, <sup>18</sup>Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia, <sup>19</sup>Department of Urology, Loma Linda University Health, Loma Linda, CA, USA, <sup>20</sup>Department of Urology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy, <sup>21</sup>Department of Urology, All India Institute of Medical Sciences, Patna, India, <sup>22</sup>Department of Urology, University of Mersin School of Medicine, Mersin, Türkiye, <sup>23</sup>Department of Urology, Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI, USA, <sup>24</sup>Andrology Department, Fundació Puigvert, Barcelona, <sup>25</sup>Instituto de Investigaciones Biomédicas Sant Pau, IIB-Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, <sup>26</sup>Department of Urology, Hamad Medical Corporation, Doha, <sup>27</sup>Department of Urology, Weill Cornell Medical-Qatar, Doha, Qatar, <sup>28</sup>Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy, <sup>29</sup>Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Cleveland, OH, <sup>30</sup>Department of Urology, The University of Chicago Medical Center, Pritzker School of Medicine, Chicago, IL, USA, <sup>31</sup>Department of Urology, Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, <sup>32</sup>Department of Urology, King Abdulaziz University, Jeddah, Saudi Arabia, <sup>33</sup>Department of Urology, Faculty of Medicine, Minia University, Minia, Egypt, <sup>34</sup>Division of Urology, Department of Surgery, The Royal Victoria Hospital, McGill University, Montreal, QC, Canada, <sup>35</sup>Cleveland Clinic Foundation, Cleveland, OH, USA

**Purpose:** Surgical sperm retrieval (SSR) is used to extract spermatozoa for use with intracytoplasmic sperm injection in men with obstructive and non-obstructive azoospermia (NOA). The procedure may lead to segmental devascularization, postoperative fibrosis, and atrophy with a subsequent decrease in testosterone. The aim of the study is to investigate the impact of SSR on serum levels of total testosterone (TT), follicle-stimulating hormone (FSH), luteinizing hormone (LH) testicular volume, and sexual function in infertile azoospermic men.

**Received:** May 24, 2024 **Revised:** Jun 1, 2024 **Accepted:** Jun 12, 2024 **Published online** Sep 10, 2024

**Correspondence to:** Ashok Agarwal  <https://orcid.org/0000-0003-0585-1026>

Global Andrology Forum (GAF), 130 West Juniper Lane, Moreland Hills, OH 44022, USA.

**Tel:** +1-216-312-5829, **E-mail:** [agarwaa32099@outlook.com](mailto:agarwaa32099@outlook.com), **Website:** <https://www.globalandrologyforum.com/>

The researchers contributing to this publication are members of the Global Andrology Forum (GAF), based in Moreland Hills, OH, USA. GAF operates under the Global Andrology Foundation, a non-profit organization registered in Innsbruck, Austria.

**Materials and Methods:** In this systematic review and meta-analysis (SRMA), we searched articles in “PubMed” and “Scopus” exploring the impact of SSR on TT, FSH, LH, and testicular volume. The full-text articles were screened to assess eligibility before data extraction, quality assessment, and meta-analysis.

**Results:** Seventeen studies meeting the inclusion criteria were finally analyzed and included 1,685 infertile, azoospermic men. Patients underwent SSR and were followed in the postoperative period (one week to 32 months). The analysis showed a significant reduction in TT (mean difference [MD] 3.81 nmol/L, 95% confidence interval [CI] 0.55:7.06;  $p=0.02$ ) compared to pre-SSR values. We also observed insignificant differences in serum FSH (MD 5.08 IU/L, 95% CI -5.6:15.8;  $p=0.35$ ), LH (MD -2.96 IU/L, 95% CI -6.31:0.39;  $p=0.08$ ), and no change in testicular volume (MD 0.07 mL, 95% CI -1.92:2.07;  $p=0.94$ ) after SSR. Sexual dysfunction was associated with hypogonadism, depression, and anxiety, especially in men with unsuccessful SSR and Klinefelter syndrome.

**Conclusions:** The results of this SRMA indicate a significant reduction in TT after SSR. Sexual dysfunction after testicular sperm extraction and the potential negative impact of future SSR repeat should be considered during preoperative counseling.

**Keywords:** Azoospermia; Hypogonadism; Microsurgical testicular sperm retrieval; Sperm injections, intracytoplasmic; Testicular sperm extraction

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

## INTRODUCTION

Surgical sperm retrieval (SSR) helps men with azoospermia to proceed with intracytoplasmic sperm injection (ICSI). There are different SSR methods. The most frequent approaches are conventional testicular sperm extraction (cTESE) [1-3] and microsurgical TESE (mTESE) [4,5]. A few years later, Amer et al [6] minimized the harvested tissues with single tubule biopsies to retrieve a sufficient number of spermatozoa. Testicular sperm aspiration (TESA) was proposed to obtain sperm cells in ejaculatory failure [7], obstructive azoospermia (OA) [8,9], and non-obstructive azoospermia (NOA) [9-11]. Other investigators used a biopsy gun needle to collect spermatozoa for ICSI, cryopreservation, and histology [12,13].

In the TESE procedure, testicular tissue samples are harvested via dissection of testicular tissue followed by tissue resection. In contrast, small pieces of tissue are aspirated in fine needle aspiration (FNA) to extract viable sperm cells. Postoperative complications, such as hematoma, devascularization, and inflammation, have been documented, eventually leading to scars and calcification [5,14,15]. Furthermore, several studies reported a significant reduction in serum testosterone levels after TESE [15,16]. Such reduction can subsequently lead to hypogonadism. The lower the total testosterone values, the more frequently the symptoms of hypogonadism appear [17,18].

Men may undergo a second TESE attempt due to the failure of the first procedure to retrieve viable spermatozoa suitable for ICSI, which occurs in almost 50% of cases [4,5]. mTESE is 1.5 times more likely than cTESE to retrieve sperm (95% confidence interval [CI] 1.4–1.6) [19]. Despite this fact, SSR may fail to harvest spermatozoa suitable for ICSI, and a second TESE procedure could also be offered to these men. The sperm retrieval rate, in this case, ranges between 18.0% and 42.8% [20-24]. The sperm retrieval rate in the third attempt goes as low as 10% [22]. Repeated TESE is also indicated if more sperm are needed for ICSI cycles or if the previously cryopreserved sperm were used up entirely in ICSI cycles [22,25].

A systematic review and meta-analysis (SRMA) indicated a transient but significant drop in testosterone levels referred to as “a temporary hypogonadism” after TESE [26]. The authors noted the challenges clinicians face when counseling patients regarding the clinical symptoms of decreased serum testosterone levels. However, the findings of this SRMA are limited by significant heterogeneity.

The current SRMA aims to explore the impact of SSR on testicular volume, serum levels of total testosterone (TT), follicle-stimulating hormone (FSH), luteinizing hormone (LH), sexual function (loss of desire, erectile dysfunction [ED], and ejaculatory disorders). This data would be instrumental in counseling men before they undergo a cTESE or mTESE procedure.

## MATERIALS AND METHODS

This study is conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement [27].

This study used a population, exposure, comparator, outcomes, and study design (PECOS) model [28]. The PECOS approach supports conducting a systematic review, including formulating the research question, determining eligibility criteria, presenting outcomes, and wording final recommendations.

### 1. Inclusion and exclusion criteria

We included studies on azoospermia (irrespective of the cause) in which men were subjected to SSR, including by cTESE, mTESE, TESA, or FNA. However, we confined the meta-analysis to mTESE for NOA because very few articles investigated other approaches to minimize the impact of various techniques on gonadal functions. The outcome measures were serum level of TT, FSH, LH, testicular volume, sexual dysfunctions as assessed by the 5-item questionnaire of the International Index of Erectile Function (IIEF-5), and long-term testicular ultrasound changes following SSR (intraparenchymal hematoma, segmental devascularization, atrophy, and calcifications). The studies included were observational before/after (case-control or cohort).

We excluded articles on SSR for the treatment of anejaculation, high sperm DNA fragmentation, and fertility preservation before cancer therapy. We also ruled out articles on epididymal sperm retrieval, whether percutaneous or microsurgical. Our review did not con-

sider animal studies, pilot studies, literature reviews, abstracts, conference papers, or book chapters.

The PECOS model of the current study is shown in Table 1.

### 2. Search strategy

A comprehensive systematic search was conducted using Scopus and PubMed. We used a combination of Medical Subject Heading (MeSH) terms and free words. The initial keyword string was created on Scopus and then was adapted to search in other databases as follows:

#### 1) Scopus

TITLE-ABS-KEY ( (azoospermia \* ) AND ( " surgical sperm retrieval " OR "TESE" or "TESA" OR "testicular sperm extraction" OR testosterone OR fsh OR "follicle-stimulating hormone" OR lh OR "luteinizing hormone" OR "oestradiol" OR "estradiol" OR "E2" OR "testicular pathology" OR "Johnsen score" ) ) AND ( LIMIT-TO ( DOCTYPE, "ar" ) )

#### 2) PubMed

"azoospermia"[All Fields] AND ("testosterone"[All Fields] OR "testosterone"[MeSH Terms] OR "fsh"[All Fields] OR "follicle stimulating hormone"[All Fields] OR "follicle stimulating hormone"[MeSH Terms] OR "lh"[All Fields] OR "luteinizing hormone"[All Fields] OR "luteinizing hormone"[MeSH Terms] OR "oestradiol"[All Fields] OR "oestradiol"[MeSH Terms] OR "estradiol"[All Fields] OR "E2"[All Fields] OR " testicular pathology "[MeSH Terms] OR "Johnsen score"[MeSH Terms] OR "IIEF" [MeSH Terms]). The databases were searched for

**Table 1.** Population, Exposure, Comparator, and Outcomes (PECO) model of the current study

|              | Inclusion                                                                                                                                                                                                                                           | Exclusion                                                                                            |
|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Population   | Men with azoospermia (irrespective of the cause)                                                                                                                                                                                                    | SSR due to anejaculation, fertility preservation before cancer therapy, high sperm DNA fragmentation |
| Exposure     | cTESE, mTESE, TESA, FNA                                                                                                                                                                                                                             | Epididymal sperm retrieval                                                                           |
| Comparison   | Preoperative data                                                                                                                                                                                                                                   | -                                                                                                    |
| Outcome      | Change in testicular volume (mL), serum levels of TT (nmol/L), LH (IU/L), FSH (IU/L), IIEF-5 score, and long-term testicular ultrasound changes following SSR (intraparenchymal hematoma, segmental devascularization, atrophy, and calcifications) | Acute complications (bleeding, hematoma, wound complications)                                        |
| Study design | Before/after, observational studies (case-control or cohort)                                                                                                                                                                                        | Animal studies, pilot studies, reviews, abstracts, conference papers, and book chapters              |

cTESE: conventional testicular sperm extraction, mTESE: microsurgical TESE, TESA: testicular sperm aspiration, FNA: fine needle aspiration, TT: total testosterone, LH: luteinizing hormone, FSH: follicle-stimulating hormone, IIEF: international index of erectile function, SSR: surgical sperm retrieval.

studies published until March 2023.

### 3. Data collection and management

#### 1) Selection of studies

The identified articles were divided equally among the research team members. Two independent members screened the retrieved abstracts. The eligibility of the identified abstracts was considered based on the inclusion and exclusion criteria of this review and following the PECOS model of this study. The full-text articles were screened to assess eligibility before data extraction and quality check. An additional search was done to identify narrative and systematic reviews on the same topic, aiming for a manual search for papers quoted in these reviews to check if any papers were missed in our database. We included articles written in English only. Fig. 1 shows the flowchart for identification, screening, and inclusion of the articles.

#### 2) Data extraction


Data extraction was conducted for potentially eligible

articles with full-text availability. Extracted information included the following: first author's name, year of publication, Journal, study design, the total number of patients, age of patients, laterality and surgical approach, and testicular pathology (intraoperative), time between SSR and assessment and study outcome parameters (pre- and post-testis size in mL [orchidometer/ultrasound], serum levels of reproductive hormones [TT, nmol/L; FSH, IU/L; LH, IU/L; IIEF-5 score, range from 5 to 25], sexual desire) and long-term ultrasound changes following surgery.

For metric and conversion unit calculation, we used Men's Hormonal health/Metric and conventional unit conversions [29].

#### 4. Quality assessment

The quality of the included studies was assessed using the Cambridge Quality Checklist [30]. Two researchers independently evaluated each study, and a third researcher resolved disagreements.



**Fig. 1.** Study flowchart showing search, screening, eligibility, and inclusion on surgical sperm retrieval-induced hypogonadism. TESE: testicular sperm extraction.



## 5. Statistical analysis

The  $I^2$  statistic and the Cochrane Q test evaluated the in-between study heterogeneity. Moderate heterogeneity was considered if the  $I^2$  was  $>40\%$ , and significant heterogeneity is regarded as  $p\text{-value} < 0.1$ . We calculated the mean difference (MD) using the following equation: The pooled mean difference was considered by subtracting the mean outcome after mTESE from the mean outcome before mTESE. The random and fixed effect models were used for high and low heterogeneity. The Restricted maximum-likelihood estimator was used to calculate the in-between study variance ( $\tau^2$ ), and the inverse variance method was used to pool the effect size. Publication bias was assessed using the funnel plot. Plot asymmetry was evaluated using Egger's test. Sensitivity analysis was done by excluding one study at a time (leave-one-out method) and observing the changes in the pooled effect size. A study is sensitive when it significantly changes the pooled effect size when removed. The statistical analysis was performed using the R programming language R version 4.1.2 with a  $p\text{-value} < 0.05$ , considered statistically significant for the overall difference between groups.


## RESULTS

Our analysis included 17 articles covering the topic of TESE and its impact on gonadal function in men with

azoospermia. The follow-up period ranged between one week and 32 months. A summary of the characteristics and main findings of the included studies are shown in Table 2. The meta-analysis included articles on mTESE only.

### 1. Change in total testosterone


This analysis included nine studies [31-39]. We removed the article by Steele et al, 2001 [40] because true cut needle biopsy was used in TESE. The follow-up in the included articles ranged between one week (one article) [40] to 14 months [34], with the majority of follow-




**Fig. 3.** Funnel plot showing publication bias for the articles on testicular volume (n=9).

| Study                  | Before mTESE |       |      | After mTESE |       |      | MD [95% CI]          |
|------------------------|--------------|-------|------|-------------|-------|------|----------------------|
|                        | Total        | Mean  | SD   | Total       | Mean  | SD   |                      |
| Akbal et al, 2010      | 36           | 27.04 | 6.93 | 36          | 9.71  | 6.93 | 17.33 [14.13; 20.53] |
| Altinkilic et al, 2018 | 78           | 13.70 | 5.50 | 71          | 11.60 | 5.00 | 2.10 [ 0.41; 3.79]   |
| Binsaleh et al, 2017   | 255          | 12.80 | 5.50 | 255         | 9.40  | 4.30 | 3.40 [ 2.54; 4.26]   |
| Eliveld et al, 2023    | 177          | 14.67 | 4.60 | 177         | 14.15 | 4.10 | 0.52 [-0.39; 1.43]   |
| Herndon et al, 2022    | 26           | 15.84 | 5.48 | 26          | 13.31 | 6.17 | 2.53 [-0.64; 5.07]   |
| Manning et al, 1998    | 15           | 17.20 | 2.75 | 15          | 12.10 | 2.92 | 5.10 [ 3.07; 7.13]   |
| Ozturk et al, 2011     | 37           | 14.10 | 2.70 | 37          | 12.83 | 2.36 | 1.27 [ 0.12; 2.43]   |
| Sertkaya et al, 2020   | 60           | 13.52 | 3.81 | 60          | 10.57 | 3.32 | 2.95 [ 1.67; 4.23]   |
| Takada et al, 2008     | 60           | 9.60  | 0.50 | 60          | 9.40  | 0.50 | 0.20 [ 0.02; 0.38]   |
| Random-effect model    | 744          |       |      | 737         |       |      | 3.81 [ 0.55; 7.06]   |


$I^2=96\%$ ,  $\tau^2=23.89$ ,  $p<0.01$   
Test for overall effect:  $p=0.02$



**Fig. 2.** Forest plot with mean difference (MD) of total testosterone (before and after mTESE; n=9). mTESE: microsurgical testicular sperm extraction, SD: standard deviation, CI: confidence interval.



**Fig. 4.** Sensitivity analysis for total testosterone analysis showing the impact of removal of individual studies on the pooled estimate. MD: mean difference, CI: confidence interval.




**Fig. 5.** Forest plot with mean difference (MD) in follicle-stimulating hormone (FSH) level (before and after mTESE). mTESE: microsurgical testicular sperm extraction, SD: standard deviation, CI: confidence interval.


up between 6 to 12 months. The meta-analysis included 744 and 737 patients in the before mTESE and after mTESE groups, respectively. The random effect model was used ( $I^2=0.96$ ,  $Q$  p-value <0.01). The pooled estimate was significantly higher in the before-TESE group (MD 3.81 nmol/L, 95% CI: 0.55:7.06;  $p=0.02$ ) (Fig. 2). The asymmetry of the funnel plot demonstrates significant publication bias ( $p=0.01$ , Egger; Fig. 3). Sensitivity analysis showed one study [36] that changed the pooled estimate when removed (Fig. 4).

## 2. Change in the FSH levels


Four studies were included [32,33,41,42]. The meta-analysis included 575 patients before mTESE and 568 patients after mTESE, respectively. The random effect model was used ( $I^2=0.98$ ,  $Q$  p-value <0.001). The pooled



**Fig. 6.** Funnel plot showing publication bias for the articles on follicle-stimulating hormone.



**Fig. 7.** Sensitivity analysis for follicle-stimulating hormone analysis showing the impact of the removal of individual studies on the pooled estimate. MD: mean difference, CI: confidence interval, KS: Klinefelter syndrome.




**Fig. 8.** Forest plot with mean difference (MD) in luteinizing hormone (LH) level (before and after mTESE). mTESE: microsurgical testicular sperm extraction, SD: standard deviation, CI: confidence interval, KS: Klinefelter syndrome.

estimate was not significantly different between the compared groups (MD 5.08 IU/L, 95% CI -5.6:15.8; p=0.35) (Fig. 5). Publication bias is demonstrated in the funnel plot (Fig. 6). Sensitivity analysis showed no studies influenced the pooled estimate when removed (Fig. 7).

### 3. Change in the LH levels


The number of studies included was three [32,35,41]. The meta-analysis included 240 and 233 patients in the before-TESE and after-TESE groups, respectively. The random effect model was used (I<sup>2</sup>=0.87, Q p-value <0.01). The pooled estimate was not significantly different between the compared groups (MD -2.96 IU/L, 95% CI -6.31:0.39; p=0.08) (Fig. 8). Publication bias is demonstrated in the funnel plot (Fig. 9). Sensitivity analysis showed that no studies influenced the pooled estimate when removed (Fig. 10).




**Fig. 9.** Funnel plot showing publication bias for the articles on luteinizing hormone (n=4).

### 4. Change in testicular volume

Three studies were included [32,37,43]. The meta-analysis included 175 and 168 patients in the before-



**Fig. 10.** Sensitivity analysis for luteinizing hormone analysis showing the impact of removal of individual studies on pooled estimate. MD: mean difference, CI: confidence interval.




**Fig. 11.** Forest plot with mean difference (MD) in testicular volume level (before and after mTESE; n=4). mTESE: microsurgical testicular sperm extraction, SD: standard deviation, CI: confidence interval.

TESE and after-TESE groups, respectively. One article was excluded [44] because the testicular volume was not compared to the preoperative values. The meta-analysis included 150 and 143 in the before and after mTESE groups, respectively. The pooled estimate was not significantly different between the compared groups (MD 0.07 mL, 95% CI -1.92;2.07; p=0.94; Fig. 11). Publication bias is demonstrated in the funnel plot (Fig. 12). Sensitivity analysis showed no studies influenced the pooled estimate when removed (Fig. 13).


## 5. Change in sexual function

Sexual dysfunction was assessed in two studies [31,34]. Akbal et al [31] evaluated the IIEF-5 in 66 men. The median IIEF-5 scores before mTESE for positive and negative TESE groups were 22 (minimum, 11; maximum, 25) and 23 (minimum, 10; maximum, 25), respectively. After SSR, IIEF-5 scores for positive and negative TESE were 23.5 (minimum, 10; maximum, 25) and 18 (minimum, 15; maximum, 25), respectively. The significant decrease was more evident in men with




**Fig. 12.** Funnel plot showing publication bias for the articles on testicular volume (n=3).

negative TESE at the end of the follow-up. Eliveld et al [34] reported sexual dysfunctions (hypoactive sexual desire and ED). Lower libido was reported in one patient out of 55 men with OA (1.8%), and 2/177 (1.1%) in



**Fig. 13.** Sensitivity analysis for testicular volume analysis showing the impact of the removal of individual studies on the pooled estimate. MD: mean difference, CI: confidence interval.



**Fig. 14.** Impact of testicular sperm extraction on spermatogenesis. FSH: follicle-stimulating hormone, LH: luteinizing hormone, GnRH: gonadotropin-releasing hormone.

NOA. ED was observed in 2/177 men with NOA (1.1%). The article did not assess ejaculatory disorders in their cohort (Table 2).

## 6. Testicular ultrasound changes

Intraparenchymal hematoma, segmental devascularization, atrophy, and calcifications were documented in two articles [40,44]. Altinkilic et al [32] observed a reversible reduction in the peak systolic velocity, which had been normalized six weeks after SSR. Steele et al [40], however, reported no hematoma on follow-up.

## DISCUSSION

In this review, an evaluation was conducted on the gonadal function in men with azoospermia following SSR. The findings of the current SRMA indicate a decline in serum TT levels after mTESE, lasting for at least 14 months. The analysis also showed insignificant changes in serum levels of FSH, LH, and testicular volume. Further, data emerging from this SRMA suggests that some men may experience ED following SSR, along with feelings of depression and anxiety.

Table 2. Summary of the included articles in our systematic review (n=17)

| No. | Study                       | Design | CQC   | No. of patients                        | Population                                   | Intervention                       | Follow up | TV                                        | Hormone                                            | Pathology                                                  | ULS                                      | HG-S                            | IIEF               |
|-----|-----------------------------|--------|-------|----------------------------------------|----------------------------------------------|------------------------------------|-----------|-------------------------------------------|----------------------------------------------------|------------------------------------------------------------|------------------------------------------|---------------------------------|--------------------|
| 1   | Eliveld et al, 2023 [34]    | Pro    | 2,3,2 | 241                                    | 53 OA, 177 NOA, and 11 KS                    | mTESE                              | 14 mo     | NA                                        | ↓ in TT in OA, no ≈ in NOA, & no ≈ in KS           | SCO (21.5%), mixed pathology (23.7%), MA (9.6%)            | NA                                       | OA (3.8%), NOA (3.3%), KS (36%) | NA                 |
| 2   | Herndon et al, 2022 [35]    | Ret    | 1,2,4 | 26                                     | NOA with failed extraction                   | mTESE                              | 6 mo      | NA                                        | ↓ in TT, significant increase in LH, FSH           | NA                                                         | NA                                       | 8/22 (36%) turned into HG       | NA                 |
| 3   | Binsaleh et al, 2017 [33]   | Ret    | 2,2,3 | 255                                    | NOA                                          | mTESE                              | 12 mo     | NA                                        | reversible ↓ in TT, FSH, and LH                    | Hypospermatogenesis (90%), MA (55.6%), SCO (39%), WTH (0%) | NA                                       | NA                              | NA                 |
| 4   | Altinkilic et al, 2018 [32] | Pro    | 1,3,3 | 78                                     | 24 OA, 54 NOA                                | tri-focal/mTESE                    | 1.5 mo    | ↓ in TV                                   | ↑ in FSH & LH, ↓ in TT                             | NA                                                         | initial ↓ in PSV & normalized in 6 weeks | NA                              | NA                 |
| 5   | Ozturk et al, 2011 [37]     | Pro    | 3,2,6 | 37                                     | NOA                                          | mTESE                              | 12 mo     | ≈ in TV                                   | ≈ in TT & FSH                                      | NA                                                         | NA                                       | NA                              | NA                 |
| 6   | Akbal et al, 2010 [31]      | Pro    | 1,3,6 | 66                                     | NOA                                          | mTESE                              | 6 mo      | NA                                        | ↓ TT, ↑ FSH, ≈ LH                                  | NA                                                         | NA                                       | NA                              | ↓ in negative TESE |
| 7   | Ishikawa et al, 2009 [41]   | Ret    | 1,2,3 | 100 46, XY NOA - 40 with nonmosaic KS  | mTESE                                        |                                    | NA        | ↓ in TT in KS ≈ NOA - ↑ in NOA, ≈ KS ≈ LH | NA                                                 | NA                                                         | Not specified                            | NA                              |                    |
| 8   | Everaert et al, 2006 [57]   | Ret    | 1,2,3 | 48                                     | FU available in 31 men with NOA              | mTESE                              |           | NA                                        | ↓ in TT, ≈ in FSH & LH                             | NA                                                         | NA                                       | Not specified                   | NA                 |
| 9   | Ramasamy et al, 2005 [42]   | Ret    | 3,2,6 | 543                                    | 435 men with NOA underwent 543 TESE attempts | 83 (15%) cTESE and 460 (85%) mTESE |           | NA                                        | ↓ 20% in testosterone after 3 and 6 mon, ≈ FSH, LH | 213 (61% SCO), 73 (21%) HG, and 62 (18%) MA                | NA                                       | NA                              | NA                 |
| 10  | Komori et al, 2004 [44]     | Pro    | 1,2,2 | 2 patients (16.7%) KS, 23 patients NOA | cTESE and mTESE                              |                                    |           | Testosterone ≈                            | No formation of ASA                                | NA                                                         | NA                                       | NA                              | NA                 |

Table 2. Continued 1

| No. | Study                       | Design | CQC   | No. of patients                                                                   | Population                                          | Interven-<br>tion | Follow<br>up | TV              | Hormone                                                                                                                          | Pathology                            | ULS                                | HG-S | IIEF |
|-----|-----------------------------|--------|-------|-----------------------------------------------------------------------------------|-----------------------------------------------------|-------------------|--------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|------------------------------------|------|------|
| 11  | Okada et al, 2002 [52]      | Ret    | 1,2,2 | Comparison of cTESE in 46 Pat. (22 OS and 24 NOA) to 100 mTESE (26 OA and 74 NOA) | cTESE and mTESE                                     |                   | ≈ in TV      | ≈ in TT         | Maturation arrest and SCO                                                                                                        | NA                                   | NA                                 | NA   | NA   |
| 12  | Westlander et al, 2001 [43] | Pro    | 2,3,2 | 35                                                                                | OA (10) NOA (25)                                    | TESA              |              | ≈ TV            | ≈ TT, ≈ FSH,                                                                                                                     | NA                                   | FTL: 4/66 6.1%), ITH (one case)    | NA   | NA   |
| 13  | Steele et al, 2001 [40]     | Pro    | 2,3,3 | 16                                                                                | OA (13), NOA (3)                                    | True cut needle   | 1 mo         | ≈ TV            | ≈ FSH, ≈ LH, ≈ TT                                                                                                                | 13 (normal spermatogenesis), 3 (SCO) | No hematoma                        | NA   | NA   |
| 14  | Manning et al, 1998 [36]    | Pro    | 1,3,6 | 15                                                                                | 15 patients with normal testosterone                | mTESE             | 12 mo        | NA              | ↓ in TT after 6 mo, but improved after 12 mo                                                                                     | NA                                   | NA                                 | NA   | NA   |
| 15  | Schill et al, 2003 [53]     | Pro    | 1,2,4 | 40                                                                                | 9 (OA) and 31 (NOA) (26 with preoperative recovery) | cTESE             |              | ≈ in 4 to 32 mo | ↓ in TT                                                                                                                          | NA                                   | 5/26 (19%) pathological conditions | NA   | NA   |
| 16  | Sertkaya et al, 2020 [39]   | Pro    | 1,3,3 | 60                                                                                | NOA                                                 | mTESE             | 1 wk         | NA              | ↓ in TT, ↑ LH                                                                                                                    | NA                                   | NA                                 | NA   | NA   |
| 17  | Takada et al, 2008 [38]     | Pro    | 2,3,3 | 69                                                                                | NOA                                                 | mTESE             | 12 mo        | NA              | ↓ in TT (recovered in hypospermatogenesis in all patients) and recovered to 50% in KS & to 80% in SCO. ↑ LH in maturation arrest | NA                                   | NA                                 | NA   | NA   |

CQC: Cambridge Quality Checklists: Correlates - Risk factors - Causal risk factors, TV: testicular volume, ULS: ultrasound, HG-S: symptoms of hypogonadism, IIEF: International Index of Erectile Function, Pro: prospective, Ret: retrospective, OA: obstructive azoospermia, NOA: non obstructive azoospermia, KS: Klinefelter syndrome, mTESE: microsurgical testicular sperm extraction, cTESE: conventional testicular sperm extraction, TT: total testosterone, MA: maturation arrest, SCO: sertoli cell only, FTI: focal testicular lesion, ITH: intra-testicular hematoma, FSH: follicle-stimulating hormone, LH: luteinizing hormone, HG: hypogonadal symptoms, PSV: peak systolic velocity, WTH: wide tubular hyalinization.  
↓: significant drop, ↑: significant increase, ≈: no change.

Hypogonadism and temporary reduction in testosterone levels have been documented after SSR [26,34]. Regarding TT reduction, our results agree with Eliveld and her team [26], who demonstrated a trend toward an increased risk for low TT by studying the odds ratios in five articles, including 147 patients before TESE and 134 patients after TESE. The authors also observed a temporary decrease in serum TT levels after TESE (below 12 nmol/L) for at least one year.

Interpreting the consequence of low testosterone levels is inconsistent, given the different cut-off levels suggested by professional societies and expert groups [12,17]. In the current analysis, we considered the last TT measurements in all the included studies, irrespective of the duration. The duration of follow-up ranged between 1 week and 14 months, with most articles evaluating the TT after 12 months. This may reflect the long-term testosterone reduction as opposed to Eliveld and colleagues' conclusions [26], who based their findings on the OR of hypogonadism rather than TT levels.

One of the crucial studies that included 435 participants with NOA who underwent 543 TESE attempts, was excluded because standard deviations were not reported [42]. However, the results of this study align with ours. The authors reported drop in TT to 80% of their pre-TESE levels in men who underwent mTESE and cTESE. The drop was observed 3 to 6 months after SSR. Fortunately, TT recovered to 85% of their baseline levels [42]. The impact of SSR on TT reduction depends on mean preoperative TT levels; based on that, the observed effects may be underestimated in individuals. A decrease in TT levels in individuals could be missed when looking at the mean levels of a cohort. Therefore, normal mean TT levels do not exclude the possibility of finding men with TT levels below 12 nmol/L who are at risk for symptoms of hypogonadism [26].

Another article by Eliveld et al [34] reported a significant drop in TT in OA (n=53). Such observation was not reported in men with NOA (n=177) and those with Klinefelter syndrome (KS) (n=11). In this latter study, the percentage of men indicated for testosterone replacement therapy (TRT) was significantly higher in KS 4/11 (36.4%) as compared with 6/177 (3.4%) and 2/53 (3.8%) in NOA and OA, respectively [34]. The authors did not mention whether TRT was indicated before SSR and whether TRT was deferred to avoid the potential negative impact on SSR success in this category

of men.

Testosterone drops due to removal of testicular tissue during TESE, thus reducing the number of Leydig cells. However, with decreased serum TT levels, the remaining Leydig cells will be stimulated by higher LH levels secondary to the hypothalamus-pituitary-gonad axis stimulation thus compensating for the gap [26]. Nevertheless, the significant drop in serum TT levels denotes that the compensatory increase in the LH levels is insufficient to maintain the eugonadal status (Fig. 14). Such a combination of high LH and normal testosterone levels is called compensated hypogonadism, as described by several investigators [41,45]. The factors that lead to uncompensated hypogonadism after SSR need to be investigated.

The inconsistent change in FSH levels in men with NOA may be due to scarring and focal segmental devascularization [5,14] and/or local germ cell loss near the scar postoperatively. It was also suggested that the peritubular scar tissue affects Leydig cells and the germ cell number [43]. The inconsistent changes in FSH and LH after micro-TESE suggest that the testes in patients with NOA who have typical sets of chromosomes (46, XY) are better able to respond than those of patients with 47, XXY. Ishikawa and his team explained this by either a defect in pituitary responsiveness in men with KS or better testicular response in men with idiopathic NOA [41]. It is also suggested that the wide tubular hyalinization of testicular tissue in men with KS provides relative immunity to peritubular scarring postoperatively, consequently, no significant differences are observed in FSH and LH at each postoperative time point [41].

A testosterone drop is directly associated with symptoms of hypogonadism, especially at levels ranging between 8 and 12 nmol/L [12]. Additionally, TT levels may also affect the chances of future TESE success. Cissen et al [46] proposed a prediction model for obtaining spermatozoa by TESE in men with NOA. They reported the following equation:  $\text{probability} = 1/[1 + \exp(-b)]$ , where  $b = -1.009 + (\text{male age} \times 0.058) + (\text{LH} \times 0.115) + (\text{LH}^2 \times 0.001) + (\text{FSH} \times -0.019) + (\text{testosterone} \times 0.034) + (\text{AZFc deletion} \times -1.480) + (\text{idiopathic NOA} \times -0.855)$  [46]. To determine the overall effect of testosterone in the given equation, the coefficient associated with the testosterone variable is 0.034. This coefficient represents the change in probability for a one-unit change in the testosterone variable, holding all other variables constant. In other

words, for each one-unit increase in testosterone, the likelihood of finding sperm increases and vice versa. Plugging the equation with testosterone reduction (by one unit) will reduce the probability of finding sperm in the next SSR attempt by approximately 0.5%. Since the MD in TT drop is 3.81 (95% CI 0.55–7.06), we can predict a reduction in SSR between 0.3% and 3.2%. However, the drop in TT is usually associated with a compensatory increase in LH and FSH levels, which means a further profound reduction in the probability of successful sperm retrieval.

Corona et al [47] investigated the TESE prediction through meta-regression analysis, which showed that testicular sperm retrieval per cycle was independent of age and hormonal parameters at enrollment. They confirmed the value of testicular volume in prediction and proposed a cut-off level of >12.5 mL for a sperm retrieval rate >60% with an accuracy of 86.2%. However, we selected the prediction model proposed by Cissen et al [46], because of the substantial bias in the meta-analysis by Corona and his team. Esteves et al [48] reported a significantly higher percentage of patients with poor prognosis subjected to mTESE than those submitted to cTESE, besides the lack of documentation of the Sertoli cell only prevalence among the included articles. Moreover, Cissen and his team [46] proposed an equation that helps clinicians predict the TESE probability of any case with NOA as long as the variables are known.

To simplify the underlying pathophysiology, it is known that androgen-binding protein transports androgen to Sertoli cells, which bind to androgen receptors to regulate spermatogenesis [49,50]. At least four steroidogenic enzymes participate in testosterone synthesis: cytochrome P450 cholesterol side chain cleavage enzyme,  $\beta$ -hydroxysteroid dehydrogenase, cytochrome P450  $17\alpha$ -hydroxylase/ $17,20$ -lyase and  $17\beta$ -hydroxysteroid dehydrogenase isoform 3. Testosterone metabolic enzyme steroid  $5\alpha$ -reductase 1 and  $3\alpha$ -hydroxysteroid dehydrogenase are expressed in some precursor Leydig cells [49]. Although the mechanism of disruption to spermatogenesis is known; its extent during and after the healing process remains unknown or somewhat unpredictable.

There is growing debate regarding hormonal therapy in eugonadal men with NOA to improve sperm retrieval [51]. Whether hormonal optimization before the second attempt, irrespective of the outcome of the first attempt, would maintain the same chance of sperm re-

trieval in the second attempt is not clear and warrants further research.

One of the signs associated with hypogonadism is a decrease in testis volume. The study by Okada et al [52] was not included in our analysis because the standard deviations were not shared. However, the authors reported that the frequency of testicular volume reduction after cTESE is ten folds higher than mTESE (10/40 [25.0%] in the cTESE group, compared to 2/80 [2.5%] in the mTESE). On the other hand, Schill et al's article [53] was excluded from the analysis because the authors reported the median values and the standard error of the mean. However, they did not document any reduction in testicular size despite reporting five pathological findings by postoperative ultrasonography.

Eliveld and her team [26] did not conduct a meta-analysis of testicular volume because all studies used different time points and TESE techniques. Nevertheless, we proceeded with the analysis despite the vast time frame ranging from six weeks [32] to 32 months [52]. Testicular size is unlikely to recover over time. Once a significant reduction in volume is observed in 6 weeks, the probability of recovery with further follow-up is remote. On the opposite side, a compensatory increase in LH and, to a lesser extent, FSH may correct TT levels. Therefore, TT follow-up for an extended period is more reasonable. The TESE technique was also not a barrier because of the iterative nature of the SSR process and wide variation in sampling number, size, intraoperative homeostasis, and closure of the tunica albuginea [54].

ED was assessed in 66 patients by Akbal et al [31]. The patients were evaluated with the IIEF-5 [55], and the Hospital Anxiety-Depression Scale [56]. Men who reported new onset ED six months after surgery, had a significant increase of FSH with insignificant elevation in LH levels, while the mean TT levels dropped significantly. Men who reported new-onset ED also reported both depression and anxiety. The authors concluded that failed SSR negatively affects erectile function due to hypogonadism, depression, and anxiety [31]. The higher probability of hypogonadism in men with unsuccessful SSR could be due to more harvested testicular tissue samples. However, the authors did not report the figures. Eliveld et al [34] reported sexual dysfunctions (hypoactive sexual desire and ED) in 4/177 (2.3%) of men with NOA and in one out of eleven men with KS (9.0%). The authors linked the sexual symptoms to

profound hypogonadism in the KS patients 4/11 (36.4%). Whether ED is related to changes in serum testosterone [31-39,57] or anxiety [31] the potential impact needs further investigations.

## CONCLUSIONS

This study has some limitations. Heterogeneity in this study stems from differences in testicular histopathology [39,58]. In addition to the variations in the number of samples harvested, other factors such as the hemostasis technique, the closure, the operative time, and the wide range of time between SSR may affect the main outcome measures.

The results of our meta-analysis suggest a significant and possibly permanent reduction of TT levels following SSR. However, due to the varying follow-up periods in this meta-analysis, a long-term follow-up study with a sufficient sample size is needed to validate our findings. We recommend exploring the changes in TT levels after the SSR procedure and linking them to future TESE success when applicable. During patient counseling, it is imperative to consider sexual dysfunction and the possible adverse effects on future TESE.

## Conflict of Interest

The authors have nothing to disclose.

## Funding

None.

## Acknowledgements

Daniela Delgadillo, BS assisted in the preparation and electronic submission of this manuscript.

## Author Contribution

Conceptualization: WZ, R Saleh, R Shah. Methodology: WZ. Data curation: WZ. Writing – original draft: all authors. Supervision: R Shah, AA. Validation: WZ. Writing – review & editing: WZ, R Saleh, AA.

## REFERENCES

1. Craft I, Bennett V, Nicholson N. Fertilising ability of testicular spermatozoa. *Lancet* 1993;342:864.
2. Schoysman R, Vanderzwalmen P, Nijs M, Segal L, Segal-Bertin G, Geerts L, et al. Pregnancy after fertilisation with human testicular spermatozoa. *Lancet* 1993;342:1237.
3. Devroey P, Liu J, Nagy Z, Tournaye H, Silber SJ, Van Steirteghem AC. Normal fertilization of human oocytes after testicular sperm extraction and intracytoplasmic sperm injection. *Fertil Steril* 1994;62:639-41.
4. Schlegel PN, Li PS. Microdissection TESE: sperm retrieval in non-obstructive azoospermia. *Hum Reprod Update* 1998;4:439.
5. Amer M, Ateyah A, Hany R, Zohdy W. Prospective comparative study between microsurgical and conventional testicular sperm extraction in non-obstructive azoospermia: follow-up by serial ultrasound examinations. *Hum Reprod* 2000;15:653-6.
6. Amer M, Zohdy W, Abd El Naser T, Hosny H, Arafa M, et al. Single tubule biopsy: a new objective microsurgical advancement for testicular sperm retrieval in patients with nonobstructive azoospermia. *Fertil Steril* 2008;89:592-6.
7. Watkins W, Bourne H, Nieto F, Gronow M, Baker G. Testicular aspiration of sperm for intracytoplasmic sperm injection: a novel treatment for ejaculatory failure on the day of oocyte retrieval. *Fertil Steril* 1996;66:660-1.
8. Hovatta O, Moilanen J, von Smitten K, Reima I. Testicular needle biopsy, open biopsy, epididymal aspiration and intracytoplasmic sperm injection in obstructive azoospermia. *Hum Reprod* 1995;10:2595-9.
9. Jensen CF, Ohl DA, Hiner MR, Fode M, Shah T, Smith GD, et al. Multiple needle-pass percutaneous testicular sperm aspiration as first-line treatment in azoospermic men. *Andrology* 2016;4:257-62.
10. Lewin A, Weiss DB, Friedler S, Ben-Shachar I, Porat-Katz A, Meirow D, et al. Delivery following intracytoplasmic injection of mature sperm cells recovered by testicular fine needle aspiration in a case of hypergonadotropic azoospermia due to maturation arrest. *Hum Reprod* 1996;11:769-71.
11. Jensen CFS, Ohl DA, Fode M, Jørgensen N, Giwercman A, Bruun NH, et al. Microdissection testicular sperm extraction versus multiple needle-pass percutaneous testicular sperm aspiration in men with nonobstructive azoospermia: a randomized clinical trial. *Eur Urol* 2022;82:377-84.
12. Tuuri T, Moilanen J, Kaukoranta S, Mäkinen S, Kotola S, Hovatta O. Testicular biopsy gun needle biopsy in collecting spermatozoa for intracytoplasmic injection, cryopreservation and histology. *Hum Reprod* 1999;14:1274-8.
13. Morey AF, Plymyer M, Rozanski TA, Deshon GE, Myers JB, Dresner ML. Biopsy gun testis needle biopsy: a preliminary

- clinical experience. *Br J Urol* 1994;74:366-9.
14. Schlegel PN, Su LM. Physiological consequences of testicular sperm extraction. *Hum Reprod* 1997;12:1688-92.
15. Donoso P, Tournaye H, Devroey P. Which is the best sperm retrieval technique for non-obstructive azoospermia? A systematic review. *Hum Reprod Update* 2007;13:539-49.
16. Shin DH, Turek PJ. Sperm retrieval techniques. *Nat Rev Urol* 2013;10:723-30.
17. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al.; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2010;95:2536-59.
18. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. *J Clin Endocrinol Metab* 2006;91:4335-43.
19. Bernie AM, Mata DA, Ramasamy R, Schlegel PN. Comparison of microdissection testicular sperm extraction, conventional testicular sperm extraction, and testicular sperm aspiration for nonobstructive azoospermia: a systematic review and meta-analysis. *Fertil Steril* 2015;104:1099-103.e1-3.
20. Xu T, Peng L, Lin X, Li J, Xu W. Predictors for successful sperm retrieval of salvage microdissection testicular sperm extraction (TESE) following failed TESE in nonobstructive azoospermia patients. *Andrologia* 2017;49:e12642.
21. Yücel C, Budak S, Keskin MZ, Kisa E, Kozacioglu Z. Predictive factors of successful salvage microdissection testicular sperm extraction (mTESE) after failed mTESE in patients with non-obstructive azoospermia: long-term experience at a single institute. *Arch Ital Urol Androl* 2018;90:136-40.
22. Amer MK, Ahmed AR, Hamid AAA, GamalEl Din SF. Factors determining the sperm retrieval rate in fresh versus salvage micro-TESE: a comparative cohort study. *Int Urol Nephrol* 2019;51:401-8.
23. Özman O, Tosun S, Bayazit N, Cengiz S, Bakırcioğlu ME. Efficacy of the second micro-testicular sperm extraction after failed first micro-testicular sperm extraction in men with nonobstructive azoospermia. *Fertil Steril* 2021;115:915-21.
24. Boeri L, Bebi C, Dente D, Greco E, Turetti M, Capece M, et al. Outcomes and predictive factors of successful salvage microdissection testicular sperm extraction (mTESE) after failed classic TESE: results from a multicenter cross-sectional study. *Int J Impot Res* 2022;34:795-9.
25. Amer M, Fakhry E. Fresh vs frozen testicular sperm for assisted reproductive technology in patients with non-obstructive azoospermia: a systematic review. *Arab J Urol* 2021;19:247-54.
26. Eliveld J, van Wely M, Meißner A, Repping S, van der Veen F, van Pelt AMM. The risk of TESE-induced hypogonadism: a systematic review and meta-analysis. *Hum Reprod Update* 2018;24:442-54.
27. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71.
28. Morgan RL, Whaley P, Thayer KA, Schünemann HJ. Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. *Environ Int* 2018;121(Pt 1):1027-31.
29. Men's Hormonal Health. Metric & conventional unit conversions [Internet]. Men's Hormonal Health [cited 2023 Jul 11]. Available from: <https://www.menshormonalhealth.com/hormone-unit-conversion-calculator.html>
30. Murray J, Farrington DP, Eisner MP. Drawing conclusions about causes from systematic reviews of risk factors: the Cambridge Quality Checklists. *J Exp Criminol* 2009;5:1-23.
31. Akbal C, Mangir N, Tavukçu HH, Özgür O, Simşek F. Effect of testicular sperm extraction outcome on sexual function in patients with male factor infertility. *Urology* 2010;75:598-601.
32. Altinkilic B, Pilatz A, Diemer T, Wolf J, Bergmann M, Schönbrunn S, et al. Prospective evaluation of scrotal ultrasound and intratesticular perfusion by color-coded duplex sonography (CCDS) in TESE patients with azoospermia. *World J Urol* 2018;36:125-33.
33. Binsaleh S, Alhajeri D, Madbouly K. Microdissection testicular sperm extraction in men with nonobstructive azoospermia: experience of King Saud University Medical City, Riyadh, Saudi Arabia. *Urol Ann* 2017;9:136-40.
34. Eliveld J, van der Bles I, van Wely M, Meißner A, Soufan AT, Heijboer AC, et al. The risk of hypogonadism after testicular sperm extraction in men with various types of azoospermia: a prospective cohort study. *Reprod Biomed Online* 2023;46:973-81.
35. Herndon CC, Godart ES, Turek PJ. Testosterone levels among non-obstructive azoospermic patients 2 years after failed bilateral microdissection testicular sperm extraction: a nested case-cohort study. *J Assist Reprod Genet* 2022;39:1297-303.
36. Manning M, Jünemann KP, Alken P. Decrease in testosterone blood concentrations after testicular sperm extraction for intracytoplasmic sperm injection in azoospermic men. *Lancet* 1998;352:37.
37. Ozturk U, Ozdemir E, Dede O, Sagnak L, Goktug HN, Gurbuz OA, et al. Assessment of anti-sperm antibodies in couples after testicular sperm extraction. *Clin Invest Med* 2011;34:E179-83.
38. Takada S, Tsujimura A, Ueda T, Matsuoka Y, Takao T, Mi-

- yagawa Y, et al. Androgen decline in patients with nonobstructive azoospermia after microdissection testicular sperm extraction. *Urology* 2008;72:114-8.
39. Sertkaya Z, Tokuç E, Özkaya F, Ertaş K, Kutluhan MA, Çulha MG. Acute effect of microdissection testicular sperm extraction on blood total testosterone and luteinising hormone levels. *Andrologia* 2020;52:e13655.
40. Steele EK, Ellis PK, Lewis SE, McClure N. Ultrasound, anti-sperm antibody, and hormone profiles after testicular Trucut biopsy. *Fertil Steril* 2001;75:423-8.
41. Ishikawa T, Yamaguchi K, Chiba K, Takenaka A, Fujisawa M. Serum hormones in patients with nonobstructive azoospermia after microdissection testicular sperm extraction. *J Urol* 2009;182:1495-9.
42. Ramasamy R, Yagan N, Schlegel PN. Structural and functional changes to the testis after conventional versus microdissection testicular sperm extraction. *Urology* 2005;65:1190-4.
43. Westlander G, Ekerhovd E, Granberg S, Lycke N, Nilsson L, Werner C, et al. Serial ultrasonography, hormonal profile and antisperm antibody response after testicular sperm aspiration. *Hum Reprod* 2001;16:2621-7.
44. Komori K, Tsujimura A, Miura H, Shin M, Takada T, Honda M, et al. Serial follow-up study of serum testosterone and antisperm antibodies in patients with non-obstructive azoospermia after conventional or microdissection testicular sperm extraction. *Int J Androl* 2004;27:32-6.
45. Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, et al.; EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. *J Clin Endocrinol Metab* 2010;95:1810-8.
46. Cissen M, Meijerink AM, D'Hauwers KW, Meissner A, van der Weide N, Mochtar MH, et al. Prediction model for obtaining spermatozoa with testicular sperm extraction in men with non-obstructive azoospermia. *Hum Reprod* 2016;31:1934-41.
47. Corona G, Minhas S, Giwercman A, Bettocchi C, Dinkelmann M, Dohle G, et al. Sperm recovery and ICSI outcomes in men with non-obstructive azoospermia: a systematic review and meta-analysis. *Hum Reprod Update* 2019;25:733-57.
48. Esteves SC, Ramasamy R, Colpi GM, Carvalho JF, Schlegel PN. Sperm retrieval rates by micro-TESE versus conventional TESE in men with non-obstructive azoospermia-the assumption of independence in effect sizes might lead to misleading conclusions. *Hum Reprod Update* 2020;26:603-5.
49. Ge RS, Li X, Wang Y. Leydig cell and spermatogenesis. *Adv Exp Med Biol* 2021;1288:111-29.
50. Wong WJ, Khan YS. Histology, sertoli cell. In: Aboubakr S, Abu-Ghosh A, Adibi Sedeh P, Aeby TC, Aeddula NR, Agadi S, et al., editors. *StatPearls*. StatPearls Publishing; 2023.
51. Tharakan T, Corona G, Foran D, Salonia A, Sofikitis N, Giwercman A, et al. Does hormonal therapy improve sperm retrieval rates in men with non-obstructive azoospermia: a systematic review and meta-analysis. *Hum Reprod Update* 2022;28:609-28.
52. Okada H, Dobashi M, Yamazaki T, Hara I, Fujisawa M, Arakawa S, et al. Conventional versus microdissection testicular sperm extraction for nonobstructive azoospermia. *J Urol* 2002;168:1063-7.
53. Schill T, Bals-Pratsch M, Küpker W, Sandmann J, Johannisson R, Diedrich K. Clinical and endocrine follow-up of patients after testicular sperm extraction. *Fertil Steril* 2003;79:281-6.
54. Vieira M, Bispo de Andrade MA, Santana-Santos E. Is testicular microdissection the only way to retrieve sperm for non-obstructive azoospermic men? *Front Reprod Health* 2022;4:980824.
55. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. *Int J Impot Res* 1999;11:319-26.
56. Brennan C, Worrall-Davies A, McMillan D, Gilbody S, House A. The Hospital Anxiety and Depression Scale: a diagnostic meta-analysis of case-finding ability. *J Psychosom Res* 2010;69:371-8.
57. Everaert K, De Croo I, Kerckhaert W, Dekuyper P, Dhont M, Van der Elst J, et al. Long term effects of micro-surgical testicular sperm extraction on androgen status in patients with non obstructive azoospermia. *BMC Urol* 2006;6:9.
58. Sussman EM, Chudnovsky A, Niederberger CS. Hormonal evaluation of the infertile male: has it evolved? *Urol Clin North Am* 2008;35:147-55, vii.